$AMPE Company News Friday’s biggest gaining and

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2013 at 9:16 PM

$AMPE Company News

Friday’s biggest gaining and declining stocks 3:26 p.m. July 13, 2012 - MarketWatch
Stocks to watch Friday: Lexmark, New York & Co. 5:47 a.m. July 13, 2012 - MarketWatch
Monday’s biggest gaining and declining stocks 3:50 p.m. June 11, 2012 - MarketWatch
Ampio: Optina has potential for diabetic treatment 11:46 a.m. June 11, 2012 - MarketWatch.com
Ampio shares add 27% after positive trial results 6:26 a.m. June 11, 2012 - Greg Morcroft
Tuesday’s biggest gaining and declining stocks 12:50 p.m. March 20, 2012 - Kate Gibson
Ampio rallies on eye-drug study 11:52 a.m. March 19, 2012 - Val Brickates Kennedy
Ampio tumbles on stock placement 2:50 p.m. Dec. 21, 2011 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 4:38 p.m. Dec. 19, 2011 - Greg Morcroft
Ampio Pharmaceuticals tumbles on drug concerns 2:57 p.m. Dec. 15, 2011 - Val Brickates Kennedy

Ampio Pharma Announces Results from Panel Review of the Interim Analysis of the Optina(TM) Trial, FDA Agrees to 505(B) 2 Pathway 6:07 a.m. Oct. 7, 2013 - benzinga.com
Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial 6:09 a.m. Sept. 30, 2013 - benzinga.com
Ampio Momentum Continues After Positive Initial Phase III Data 2:57 p.m. Aug. 26, 2013 - Seeking Alpha
Strong Phase III Ampion Data Released Wednesday: Setting The Stage For Ampio 7:12 a.m. Aug. 15, 2013 - Seeking Alpha
10-Q: AMPIO PHARMACEUTICALS, INC. 4:06 p.m. Aug. 9, 2013 - Edgar Online - (EDG = 10Q, 10K)
Raghuram 'Ram' Selvaraju On The Best Biotech Ideas Of 2013 7:20 a.m. July 22, 2013 - Seeking Alpha
What The Snubbing Of Hyaluronic Acid By The AAOS Means For Investors 8:41 a.m. June 25, 2013 - Seeking Alpha
Ampio Pharma's Luoxis Diagnostics Reports Positive Results from First Study of Proprietary Diagnostic Platform 6:06 a.m. June 20, 2013 - benzinga.com
Ampio Pharmaceuticals: 50 Shades Of Grey - Secondary On The Way 3:53 p.m. June 6, 2013 - Seeking Alpha
2 Potentially Explosive Small Cap Stocks For 2013 3:53 a.m. May 30, 2013 - Seeking Alpha
Regeneron Shareholders Watching Optina Trial Closely 2:56 p.m. May 22, 2013 - Seeking Alpha
10-Q: AMPIO PHARMACEUTICALS, INC. 4:04 p.m. May 3, 2013 - Edgar Online - (EDG = 10Q, 10K)
Ampio Pharma Initiates Phase III, Investors Extend Momentum 8:39 a.m. May 3, 2013 - Seeking Alpha
Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee 6:03 a.m. April 25, 2013 - benzinga.com
Lucrative AMD And DME Markets Attract Wall Street To Regeneron And Other Players 12:43 p.m. April 3, 2013 - Seeking Alpha
Ampio Receives FDA Acceptance for Clinical Trial of Ampion for Treatment of Osteoarthritis of the Knee 4:05 a.m. April 2, 2013 - benzinga.com
10-K: AMPIO PHARMACEUTICALS, INC. 6:05 a.m. March 6, 2013 - Edgar Online - (EDG = 10Q, 10K)
UPDATE: Aegis Capital Reiterates Buy Rating, Raises PT on Ampio Pharmaceuticals on Clinical Milestones 7:10 a.m. March 4, 2013 - benzinga.com
4 Healthcare Stock Stories to Keep Investors Well 3:57 p.m. Feb. 27, 2013 - Wall St. Cheat Sheet
Ampio Pharmaceuticals Begins Clinical Trial of Optina for Diabetic Macular Edema 4:54 a.m. Feb. 27, 2013 - benzinga.com

Ampio Pharmaceuticals Reports Positive Results in the Extended Spring study of Osteoarthritis of the Knee Following a Single Intra-articular Injection of Ampion(TM) 8:00 a.m. Nov. 4, 2013 - PR Newswire
Ampio Pharmaceuticals, Inc. States that its Policy is Not to Comment on Unusual Market Activity 7:00 a.m. Oct. 25, 2013 - PR Newswire
Emerging Growth Equities, Ltd. Initiates Coverage Of Ampio Pharmaceuticals, Inc. (AMPE) With A BUY Rating And $14.00 Price Target 9:21 a.m. Oct. 11, 2013 - PR Newswire
Ampio Pharmaceuticals, Inc. Announces Positive Results from Independent Panel Review of the Interim Analysis of the Optina(TM) Trial for Diabetic Macular Edema 7:00 a.m. Oct. 7, 2013 - PR Newswire
Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of company's third US patent for its oxidation-reduction potential diagnostic platform 7:00 a.m. Oct. 1, 2013 - PR Newswire
Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial 7:00 a.m. Sept. 30, 2013 - PR Newswire
Ampio Pharmaceuticals, Inc. Announces $25 Million Financing 5:00 a.m. Sept. 26, 2013 - PR Newswire
Five Star Equities Issues New Research Reports on AMPE, BIOS, MM and XONE 7:31 a.m. Aug. 15, 2013 - ACCESSWIRE
Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial 7:00 a.m. Aug. 14, 2013 - PR Newswire
Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog 7:00 a.m. June 7, 2013 - PR Newswire
Ampio Pharmaceuticals to List on the NYSE MKT 7:00 a.m. June 6, 2013 - PR Newswire
Ampio Pharmaceuticals Provides Clinical Updates 7:00 a.m. June 3, 2013 - PR Newswire
Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference 7:00 a.m. May 13, 2013 - PR Newswire
Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee 7:00 a.m. April 25, 2013 - PR Newswire
Ampio Receives FDA Clearance to Initiate Clinical Trial of Ampion(TM) for the Treatment of Osteoarthritis of the Knee: Patient Treatments have begun. 3:00 a.m. April 2, 2013 - PR Newswire
Ampio Receives FDA Acceptance of its Patient Outcome for Premature Ejaculation (POPE) Questionnaire, Paving the Way for its US Pivotal Trial on Zertane(TM) 3:00 a.m. March 11, 2013 - PR Newswire
LifeSci Advisors Initiates Coverage of Ampio Pharmaceuticals 8:02 a.m. March 7, 2013 - Marketwire
Ampio Pharmaceuticals Initiates Clinical Trial of Optina(TM) in Diabetic Macular Edema (DME): First Patient Dosed 4:00 a.m. Feb. 27, 2013 - PR Newswire
Ampio Pharmaceuticals Modifies Ampion(TM) IND for Osteoarthritis of the Knee to Include A Dose Escalation Run-In Study and Prepares to Launch Pivotal Clinical Trial 4:00 a.m. Feb. 25, 2013 - PR Newswire
Ampio forms Luoxis Diagnostics to Commercialize ORP Technology 4:00 a.m. Feb. 11, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Metropolitan at The 9 Unveils Major Renovation in 2026

A Cleveland Gem Gets a Makeover Alright, listen up—Metropolitan at The 9 in Cleveland has undergone a massive facelift. We're talking about a complete overhaul of every single one of its 156 guestrooms and suites, new elevators, a refreshed lobby, and a reimagined Ledger Bar. Details and Delights in Every Corner Let's dig into the nitty-gritty. Guests are walking into...

Century Communities Unveils New Homes Near Austin

New Opportunities in the Lone Star State Century Communities, Inc. (NYSE: CCS) is cranking up the heat in the real estate market with their latest attraction—Crosswinds in Kyle, Texas. This isn't just another cookie-cutter development; it's packing in excitement with a grand opening on October 28. From model home tours to early-bird savings, they're pulling out all the...

CPSC's Management Overhaul: Progress or Just Polishing?

The Tangled Web of Bureaucracy Ah, the Consumer Product Safety Commission—CPSC for short. It's like the Secretariat of product safety, but often knee-deep in old problems. Over the years, hearing about their challenges is like flipping through a well-worn playbook. But now, the talk is all about a fresh page under Acting Chairman Peter A. Feldman. The watchdog in...

Post University Expands with New Tech and Health Degrees

If you're looking to invest in an education with promising payoffs, you might look into what's cooking over at Post University. They've just dropped a bombshell of new programs sure to get some attention from tech heads and health nuts alike, and I can't help but think there's potential brewing here. New Academic Paths Emerge Post University isn't resting on its...

Cumberland Pharmaceuticals Eyes NDA for Ifetroban in DMD

Rolling the Dice with Ifetroban There's a buzz in the air around Cumberland Pharmaceuticals as they gear up to tackle one of medicine's stubborn giants, Duchenne muscular dystrophy (DMD). They plan to file a New Drug Application (NDA) with the FDA for ifetroban, aiming to treat the cardiomyopathy plaguing many DMD sufferers. Folks who’ve watched Cumberland (NASDAQ:CPIX)...

Natural Field Reinvents Supplement Delivery at SupplySide

Pioneering New Frontiers in Supplement Delivery Sometimes you can taste the winds of change in your morning coffee, and this time it’s in the world of dietary supplements. SupplySide Global 2026 is shaking up the scene, folks, and Natural Field Co., Ltd. is leading that charge with some pioneering approaches that might just redefine how we gulp our health aids. Beyond...

Costa Rican Firms Target Aerospace Supply Chain Gains

Today's spotlight swings on a gutsy move by 10 Costa Rican aerospace companies hustling for a foothold on the global stage. These folks aren't just sitting back; they're throwing their hats in the ring at the NBAA-BACE shindig down in the neon glare of Las Vegas, aiming to muscle into the aerospace supply chain — a cold, hard leap that's a mix of grit and ambition....

LuminoCity Expands with B2B Entertainment Showcase

Big Lights, Immersive Action In an age where entertainment must be larger-than-life, LuminoCity seems to have figured out how to transform the ordinary into the extraordinary. The folks over at LuminoCity Festival have rolled out a strategy to supercharge their business-to-business (B2B) offerings, aiming to bring immersive entertainment solutions to parks, zoos, and...

PG&E Halts Service; Groups Demand Regulatory Action

Pending Storm Over PG&E's Service Delays It's rare that you hear a utility company flat-out say it can't afford to keep the lights on. Yet here we are, staring down the barrel of some unsettling news for 25,000 PG&E customers. They've been warned they might cool their heels for an extra six months before their service is up and running. As if that's not dicey enough, $2...

XCMG Climbs Fortune China 500: Strengthens Global Edge

XCMG's Ascent on the Fortune China 500 When it comes to scaling new heights, XCMG Machinery is clearly in the driver's seat, roaring up the Fortune China 500 to claim the 202nd spot, leaping ten ranks from last year. While others may coast, XCMG's trajectory is anything but idle, retaining its crown among Chinese construction machinery titans. The recent summit in Chengdu...